Bristol-Myers Squibb (BMY) has been in focus after its board declared a quarterly dividend of $0.63 per share, payable on August 3, 2026, to shareholders of record on July 2, 2026.

At a latest share price of $54.70, Bristol-Myers Squibb has had a mixed run, with a 30-day share price return down 8.01% but a 1-year total shareholder return of 22.41%, suggesting recent momentum has cooled after a stronger year.

If this dividend update has you thinking about where else growth and income might come from in healthcare, consider scanning for other opportunities across 38 healthcare AI stocks

So with Bristol-Myers Squibb offering a 4.6% dividend yield, a recent share price pullback, a reported intrinsic discount of 54.52% and a 16.32% gap to analyst targets, is the stock a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 13.1% Undervalued

Compared with the last close at $54.70, the most followed narrative puts Bristol-Myers Squibb’s fair value at $62.96, using a 7.11% discount rate to weigh its future cash flows and risks.

Robust late-stage pipeline and ongoing life-cycle management for major brands, plus strategic partnerships (BioNTech, Philochem, Bain), expand the breadth of future regulatory approvals and label expansions, opening additional indications and helping to offset upcoming patent expiries, which underpins top-line and earnings growth.

Want to see what sits behind that valuation gap? The narrative leans on shifting revenue mix, changing margin profile and a higher future earnings multiple. The exact trade offs are worth a look.

Result: Fair Value of $62.96 (UNDERVALUED)

However, Bristol-Myers Squibb still faces meaningful risks, including patent cliffs for key drugs like Eliquis and Opdivo, as well as pressure on pricing and margins in its core U.S. market.

Another View: What Multiples Say About Bristol-Myers Squibb

While the most followed narrative points to Bristol-Myers Squibb trading below fair value, the current P/E of 15.4x sits slightly above the US Pharmaceuticals industry at 14.9x but below a fair ratio of 18.6x and the peer average of 21.7x. This sends a mixed signal on valuation risk and potential upside, so which reference point do you put more weight on?

Next Steps

With mixed signals across Bristol-Myers Squibb’s valuation and narrative, the real question is how you weigh the company’s risks against its potential rewards. Move quickly, review the data, and test your own thesis against the 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond Bristol-Myers Squibb?

If Bristol-Myers Squibb has sharpened your focus, do not stop here. Broaden your watchlist so you are not relying on a single story for returns.

• Start with income potential by scanning companies that aim to sustain payouts using the 7 dividend fortresses.
• Pursue value opportunities by comparing current prices with business quality using the 44 high quality undervalued stocks.
• Prioritize resilience by filtering for companies with stronger balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.